Excited to share my JMP!
Do academic fields of study causally influence students' political preferences? Through what mechanisms? And what are the broader civic implications?
๐ #EconJobMarket#EconTwitter
Joint with @matankoler (PhD @HebrewU, now postdoc @MITEcon)
Large productivity gains from AI don't lead to equally big gains in software.
+40%/+140%/+180% commits from autocomplete/interactive/autonomous agents but only +50%/+30% projects/releases
And does this new software get used by consumers? Not really. It's invisible/irrelevant.
People who don't follow cancer research often ask me why we haven't cured cancer. That perception masks a wonderful reality: We make amazing, stepwise progress every year, and the result is that many people live much longer today than they would have previously.
Right now we're in the thick of the annual meeting of the American Society of Clinical Oncology, the biggest research meeting on new cancer medicines, and this morning a bunch of really important studies dropped. I'm going to review them here.
This first image is the result for daraxonrasib, a treatment for pancreatic cancer that is generating consdirable excitement. The green line is the probability of living for patients who got the new drug; the gray one is the chemo control group.
If you follow cancer drugs, a chart like this will make your breath hitch a little. I'm going to review these and some other data here.